Phio Pharmaceuticals reports 2023 net loss of $10.8M; cash at $8.5M with PH-762 trial progress

Phio Pharmaceuticals Corp.

2024-Q1 EPS reported -$0.47

Net loss $10.8M ($5.20/share) vs $11.5M ($10.10/share) in 2022; R&D expenses down 10% to $6.3M.
Cash at Dec 31, 2023: $8.5M, down from $11.8M at end of 2022.
PH-762 Phase 1B: two patients completed treatment with no adverse events; four clinical sites under contract.
Headcount reduced 36% and Marlborough lease not renewed; moved to 321 sq ft lab in Worcester.
AgonOx study delayed; facility renovation expected to reopen May 2024; third patient infused in Nov 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phio Pharmaceuticals Corp. reported the year ended December 31, 2023 results: net income $10.8 million, EPS $5.20 per share.

Period: the year ended December 31, 2023
Net income: $10.8 million
EPS: $5.20 per share
Result: reported results

Exact text from the filing

Net loss was $10.8 million, or $5.20 per share, for the year ended December 31, 2023

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-24-002050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.